Prostate Cancer Biomarkers to Predict Recurrence and Metastatic Potential

Described herein are methods for predicting the recurrence, progression, and metastatic potential of a prostate cancer in a subject. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of FOXO1A, SOX9, CLNS1A, PTGDS, XPO1, LETMD1, RAD23B, ABCC3, APC, CHES1, EDNRA, FRZB, HSPG2, and TMPRSS2_ETV1 FUSION. The method can further comprise detecting in a sample from a subject one or more biomarkers selected from the group consisting of miR-103, miR-339, miR-183, miR-182, miR-136, and miR-221. An increase or decrease in one or more biomarkers as compared to a standard indicates a recurrent, progressive, or metastatic prostate cancer.

Attached files:
WO 2010056993.jpg

Patents:
WO 2,010,056,993

Inventor(s): MORENO CARLOS [US]; OSUNKOYA ADEBOYE [US]; ZHOU WEI [US]; LEYLAND-JONES BRIAN [US]; LONG QI [US]; JOHNSON BRENT A [US]

Type of Offer: Licensing



Next Patent »
« More Biotech Patents

Share on      


CrowdSell Your Patent